Novo Nordisk’s European Breakthrough Tempered by Growing Generics Threat in Brazil and Beyond
France will publicly reimburse Wegovy and Mounjaro, and EMA backs new oral and high-dose versions, but Brazil’s first…
From Chatbots to Chemists: Novo Nordisk’s Wegovy Pill Surges as Canadian Generics Undercut Ozempic
Novo Nordisk’s Wegovy leads weight-loss drug search results on AI chatbots, but generic semaglutide enters Canadian pharmacies at…
Novo Nordisk Battles Pricing Storm on Two Fronts as Canadian Generics and US Policy Converge
US TrumpRx portal adds 600+ generic drugs, Canada approves first Ozempic generics, pressuring Novo Nordisk stock (down 15%…
Novo Nordisk’s Generics Defence in India Offers Blueprint as Amazon Widens US GLP-1 Access
Novo Nordisk’s Ozempic and Wegovy sales rose 40% in India after patent expiry, as generics expand the market.…
Novo Nordisk’s Oral Wegovy Breaks Records, but Generics Threaten to Undercut the Party
Novo Nordisk’s oral Wegovy pill generated 2.26B DKK in Q1, doubling analyst estimates, but generic semaglutide launches in…
Novo Nordisk’s Pill Push Eases the Pain, but the Generics Are Already Circling
Novo Nordisk beats Q1 expectations, raises guidance, and launches oral Ozempic in the US, but adjusted revenue falls…
Generics, Pipeline Wins, and a Pivotal Earnings Report
Novo Nordisk enters a pivotal week with Canada approving first Ozempic generics, oral Ozempic exceeding prescription expectations, and…
Generics, Q1 Results, and a Pipeline Showcase
Novo Nordisk enters a critical period with Q1 earnings, a Canadian Ozempic generic launch, and obesity conference data,…
Generics, Price Wars, and a Steep Valuation Gap
Novo Nordisk faces a turbulent period with a 20% stock drop, Eli Lilly’s US market dominance, and Canada’s…
Novo Nordisk’s Oral Wegovy Pill Surges Past Eli Lilly, but Generics and Price Pressure Loom
Novo Nordisk’s oral Wegovy pill leads Eli Lilly’s Foundayo 2-to-1 in US prescriptions, but faces generic competition in…
Novo Nordisk patent expiry opens door to cheaper weight-loss drugs in India
By Rishika Sadam HYDERABAD, March 19 (Reuters) – India’s market for diabetes and weight-loss drugs is set for…
Novo Nordisk patent expiry opens door to cheaper weight-loss drugs in India
By Rishika Sadam HYDERABAD, March 19 (Reuters) – India’s market for diabetes and weight-loss drugs is set for…